Bellevue Life Sciences Faces Delisting Notice

TL;DR

BLAC got a delisting warning, might be in trouble.

AI Summary

Bellevue Life Sciences Acquisition Corp. filed an 8-K on October 10, 2024, reporting a notice of delisting or failure to satisfy continued listing rules as of October 4, 2024. The company, incorporated in Delaware, is involved in the Surgical & Medical Instruments & Apparatus industry.

Why It Matters

This filing indicates potential issues with the company's ability to remain listed on its exchange, which could impact its stock liquidity and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards is a significant negative event that can lead to severe consequences for the company and its shareholders.

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Registrant
• October 4, 2024 (date) — Date of earliest event reported
• October 10, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• 3841 (industry_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma

Filing Documents

• d846929d8k.htm (8-K) — 28KB
• 0001193125-24-235949.txt ( ) — 206KB
• blacu-20241004.xsd (EX-101.SCH) — 5KB
• blacu-20241004_def.xml (EX-101.DEF) — 15KB
• blacu-20241004_lab.xml (EX-101.LAB) — 26KB
• blacu-20241004_pre.xml (EX-101.PRE) — 16KB
• d846929d8k_htm.xml (XML) — 9KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 4, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-41390 84-5052822 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 10900 NE 4th Street , Suite 2300 , Bellevue , WA 98004 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code (425) 635-7700 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Units, each consisting of one share of common stock, one redeemable warrant and one right BLACU The Nasdaq Stock Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Market LLC Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Market LLC Right to receive one-tenth (1/10) of one share of common stock BLACR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on February 15, 2024, the Company received a letter (the "Notice") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that the Company no longer meets the minimum 300 public holders requirement for The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(3) (the "Minimum Public Holders Requirement"). On April 1, 2024, the Company submitted to Nasdaq a plan to regain compliance with the Minimum Public Holders Requirement and, on April 17, 2024, the staff of Nasdaq approved the plan and granted the Company an extension until August 13, 2024 to demonstrate compliance with the Minimum Public Holders Requirement (the "Compliance Period"). On August 20, 2024, the Company received written notice (the "Second Notice") from Nasdaq stating that the Company has not regained compliance with the Minimum Public Holders Requirement within the Compliance Period. In accordance with the Second Notice, the Company timely requested a hearing before the Hearings Panel (the "Panel"), which automatically stayed any suspension or delisting action of the Company's securities, and the hearing was held on October 1, 2024. On October 4, 2024, the Panel granted the Company's request for continued listing on the Nasdaq, subject to the requirement that on or before February 17, 2025, the Company shall demonstrate compliance with Listing Rule 5505, and that during the exception period, the Company shall provide prompt notification of any significant events that occur during this time that may affect the Company's compliance with Nasdaq requirements. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 10, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR